A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms

Table 5

The results of group and subgroup analyses according to the comparison of mean WHAQ scores changes within groups.

	Within group
Repeated ANOVA
		Premenstrual				Menstrual				Postmenstrual
Mean WHAQ scores*		DSG; (±SE)	Sig.	DRSP; (±SE)	Sig.	DSG; (±SE)	Sig.	DRSP; (±SE)	Sig.	DSG; (±SE)	Sig.	DRSP; (±SE)	Sig.
	Baseline–3rd cycle	0.42 ± 0.41	0.307	6.56 ± 0.79	0.000	−0.69 ± 0.34	0.046	4.44 ± 0.76	0.000	−0.11 ± 0.26	0.672	1.36 ± 0.34	0.000
Total	Baseline–6th cycle	3.24 ± 0.77	0.000	13.71 ± 1.25	0.000	1.73 ± 0.63	0.008	9.93 ± 0.96	0.000	0.47 ± 0.30	0.132	1.87 ± 0.45	0.000
	3rd cycle–6th cycle	2.82 ± 0.65	0.000	7.16 ± 0.91	0.000	2.42 ± 0.58	0.000	5.49 ± 0.55	0.000	0.58 ± 0.27	0.041	0.51 ± 0.25	0.050
	Baseline–3rd cycle	0.42 ± 0.19	0.031	2.31 ± 0.45	0.000	0.04 ± 0.17	0.800	1.58 ± 0.45	0.001	0.04 ± 0.13	0.736	0.58 ± 0.21	0.008
Negative effect	Baseline–6th cycle	2.16 ± 0.44	0.000	5.82 ± 0.58	0.000	1.49 ± 0.33	0.000	4.36 ± 0.50	0.000	0.38 ± 0.18	0.039	1.31 ± 0.23	0.000
	3rd cycle–6th cycle	1.73 ± 0.40	0.000	3.51 ± 0.43	0.000	1.44 ± 0.30	0.000	2.78 ± 0.39	0.000	0.33 ± 0.15	0.034	0.73 ± 0.18	0.000
	Baseline–3rd cycle	0.20 ± 0.13	0.130	1.87 ± 0.27	0.000	−0.64 ± 0.17	0.000	1.20 ± 0.31	0.000	−0.20 ± 0.12	0.107	0.40 ± 0.14	0.005
Water retention	Baseline–6th cycle	0.844 ± 0.32	0.012	3.53 ± 0.46	0.000	−0.36 ± 0.37	0.345	2.29 ± 0.39	0.000	−0.02 ± 0.14	0.872	0.53 ± 0.18	0.005
	3rd cycle–6th cycle	0.644 ± 0.31	0.040	1.67 ± 0.32	0.000	0.29 ± 0.31	0.365	1.09 ± 0.25	0.000	0.18 ± 0.12	0.132	0.13 ± 0.11	0.225
	Baseline–3rd cycle	0.38 ± 0.18	0.036	2.58 ± 0.38	0.000	0.60 ± 0.21	0.007	2.24 ± 0.40	0.000	0.11 ± 0.14	0.417	0.51 ± 0.18	0.006
Impaired concentration	Baseline–6th cycle	1.22 ± 0.34	0.001	4.91 ± 0.63	0.000	1.36 ± 0.29	0.000	4.16 ± 0.52	0.000	0.36 ± 0.17	0.041	0.82 ± 0.18	0.000
	3rd cycle–6th cycle	0.84 ± 0.28	0.005	2.33 ± 0.46	0.000	0.76 ± 0.23	0.002	1.91 ± 0.29	0.000	0.24 ± 0.16	0.140	0.31 ± 0.11	0.009
	Baseline–3rd cycle	−0.11 ± 0.14	0.417	0.76 ± 0.12	0.000	−0.04 ± 0.10	0.643	0.69 ± 0.14	0.000	−0.18 ± 0.11	0.103	0.16 ± 0.08	0.051
Increased appetite	Baseline–6th cycle	−0.20 ± 0.18	0.284	1.02 ± 0.18	0.000	0.16 ± 0.18	0.399	1.18 ± 0.18	0.000	−0.07 ± 0.12	0.570	0.16 ± 0.10	0.128
	3rd cycle–6th cycle	−0.09 ± 0.13	0.486	0.27 ± 0.13	0.050	0.20 ± 0.14	0.162	0.49 ± 0.14	0.001	0.11 ± 0.09	0.229	0.00 ± 0.08	1.00
	Baseline–3rd cycle	−0.47 ± 0.12	0.000	−0.96 ± 0.12	0.000	−0.58 ± 0.12	0.000	−1.27 ± 0.16	0.000	0.11 ± 0.12	0.375	−0.29 ± 0.15	0.068
Feeling of well being	Baseline–6th cycle	−0.78 ± 0.13	0.000	−1.58 ± 0.13	0.000	−0.84 ± 0.16	0.000	−1.98 ± 0.16	0.000	−0.18 ± 0.15	0.242	−0.96 ± 0.11	0.000
	3rd cycle–6th cycle	−0.31 ± 0.12	0.015	−0.62 ± 0.12	0.000	−0.27 ± 0.13	0.038	−0.71 ± 0.17	0.000	−0.29 ± 0.15	0.063	−0.67 ± 0.14	0.000
	Baseline–3rd cycle	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—
Undesirable hair changes	Baseline–6th cycle	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—
	3rd cycle–6th cycle	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—	0.00 ± 0.00	—

 DSG: desogestrel and DRSP: drospirenone.
 *Mean WHAQ scores were calculated from summed scores of all the subjects divided by the number of subjects.